322 related articles for article (PubMed ID: 34537893)
1. Fibroblast activation protein targeted therapy using [
Liu Y; Watabe T; Kaneda-Nakashima K; Shirakami Y; Naka S; Ooe K; Toyoshima A; Nagata K; Haberkorn U; Kratochwil C; Shinohara A; Hatazawa J; Giesel F
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):871-880. PubMed ID: 34537893
[TBL] [Abstract][Full Text] [Related]
2. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
3. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
4. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
5.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
6. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
[TBL] [Abstract][Full Text] [Related]
8. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
9. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
10. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.
Martin M; Ballal S; Yadav MP; Bal C; Van Rymenant Y; De Loose J; Verhulst E; De Meester I; Van Der Veken P; Roesch F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980775
[TBL] [Abstract][Full Text] [Related]
11. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
12. Clinical translational evaluation of Al
Wang S; Zhou X; Xu X; Ding J; Liu S; Hou X; Li N; Zhu H; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4259-4271. PubMed ID: 34165601
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
15. Impact of
Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
[TBL] [Abstract][Full Text] [Related]
16. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
17.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
[TBL] [Abstract][Full Text] [Related]
19. Radiation Dosimetry and Biodistribution of
Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
[TBL] [Abstract][Full Text] [Related]
20. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
